Journey Medical Q1 revenue $16M (+21% YoY); Emrosi sales triple to $6.3M

Journey Medical Corp

Total revenue $16.0M, +21% YoY vs $13.1M; Emrosi revenue $6.3M vs $2.1M in Q1 2025.
Net loss narrowed to $2.2M ($0.08 loss per share) from $4.1M ($0.18 loss per share) YoY.
Adjusted EBITDA turned positive at $0.6M ($0.02 per share) vs negative $0.9M in Q1 2025.
Cash increased to $27M; gross margin 61% impacted by $1.3M non-cash API write-down.
SG&A down $0.5M to $10.1M due to lower Emrosi launch costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.